We are constantly working to ensure that patients in our region have direct access to innovative products.
Our active portfolio includes novel branded pharmaceutical products of high therapeutic value, many of which are biotech. Most of these pharmaceutical products are intended exclusively for hospital use.
According to the European Medicines Agency, between 5,000 and 8,000 distinct rare diseases exist, affecting between 6% and 8% of the population in total – in other words, around 27 to 36 million people in the EU. Genesis currently has 11 orphan products in its active portfolio targeting diseases that include multiple myeloma, soft-tissue sarcoma, ovarian cancer, Fabry disease as well as hereditary ATTR (hATTR) amyloidosis. We are actively working in bringing to market new innovative therapies that will address the unmet therapeutic needs of patients living with rare and orphan diseases.